Triptorelin
Trelstar / Decapeptyl / GnRH agonist
Triptorelin is a synthetic GnRH agonist (decapeptide analog) that is approximately 100 times more potent than native GnRH, used primarily for sustained suppression of the reproductive axis. It is FDA-approved as Trelstar for the treatment of advanced prostate cancer through chemical castration via continuous GnRH receptor stimulation. In research and clinical contexts, it is also used in post-cycle therapy (PCT) protocols to restart the hypothalamic-pituitary-gonadal axis after anabolic steroid use.
作用机制
Potent GnRH agonist with greatly enhanced receptor binding affinity. Initial administration causes a flare of LH/FSH and testosterone. Continuous administration leads to profound suppression of the HPG axis via pituitary GnRH receptor downregulation.
研究协议
仅供研究使用,非医疗建议。
Research protocols use 50-100mcg as a single dose for hormonal reset. Depot formulations (3.75mg monthly, 11.25mg quarterly, 22.5mg semi-annual) used for sustained suppression. Anti-suppressive protocols use micro-dosing.
研究笔记
Clinical Research Status
Triptorelin holds FDA approval for advanced prostate cancer (Trelstar, in depot formulations of 1-month, 3-month, and 6-month durations) and is approved in Europe for additional indications including endometriosis and precocious puberty. Research has explored single-dose triptorelin (100 mcg) for HPG axis recovery following androgen-induced hypogonadism. The European Medicines Agency also recognizes its use in assisted reproduction protocols for ovulation triggering.
Key Published Findings
A landmark 2010 study (Mourelatos et al.) demonstrated that a single 100 mcg injection of triptorelin could restore gonadotropin levels in men with anabolic steroid-induced hypogonadism within 1-2 weeks. In prostate cancer, depot formulations reduce testosterone to castrate levels (<50 ng/dL) within 2-4 weeks after an initial transient surge. Clinical trials confirm sustained efficacy for testosterone suppression over 6-12 month treatment periods.
Safety Profile
The initial GnRH agonist flare (temporary testosterone increase in the first 1-2 weeks) can exacerbate prostate cancer symptoms and typically requires concurrent anti-androgen coverage. Long-term use causes expected effects of hypogonadism: hot flashes, decreased libido, bone density loss, and metabolic changes. In PCT use, the single low-dose protocol (100 mcg) has minimal reported adverse effects due to the brief exposure duration.
Comparison to Related Compounds
Compared to other GnRH agonists (leuprolide, goserelin), triptorelin has similar efficacy for testosterone suppression but differs in formulation options and pharmacokinetics. For PCT purposes, triptorelin's single-dose protocol contrasts with the multi-week SERM-based approaches using clomiphene or tamoxifen. Unlike gonadorelin which stimulates at pulsatile doses, triptorelin's continuous receptor activation leads to desensitization and suppression after the initial stimulatory phase.
Community Observations
In PCT contexts, the single 100 mcg triptorelin injection protocol has gained popularity as a rapid HPG axis restart option, though evidence remains limited to small studies. Practitioners caution that doses above 100 mcg risk prolonged suppression rather than recovery, making precise dosing critical. Most PCT experts recommend combining triptorelin with SERMs rather than using it as a standalone restart agent for optimal recovery outcomes.
半衰期
~3-5 hours (daily form); 28 days (depot)
复溶
Sterile water for injection
存储
冻干
Refrigerate 2-8C.
复溶后
Use immediately after reconstitution for depot forms.
美国法律状态
又称作
常见问题
什么是 Triptorelin?
Triptorelin is a synthetic GnRH agonist (decapeptide analog) that is approximately 100 times more potent than native GnRH, used primarily for sustained suppression of the reproductive axis. It is FDA-approved as Trelstar for the treatment of advanced prostate cancer through chemical castration via continuous GnRH receptor stimulation. In research and clinical contexts, it is also used in post-cycle therapy (PCT) protocols to restart the hypothalamic-pituitary-gonadal axis after anabolic steroid use.
Triptorelin 如何起作用?
Potent GnRH agonist with greatly enhanced receptor binding affinity. Initial administration causes a flare of LH/FSH and testosterone. Continuous administration leads to profound suppression of the HPG axis via pituitary GnRH receptor downregulation.
Triptorelin 在美国的监管状态是什么?
FDA-approved (Rx only)
Triptorelin 的半衰期是多少?
~3-5 hours (daily form); 28 days (depot)
Triptorelin 还有哪些名称?
Trelstar, Decapeptyl, GnRH agonist
Peptide Contacts仅提供基于研究的摘要,仅供信息参考。我们不托管、分发或支持供应商文档。所有证书分析、GMP证书和供应商通信必须由买家直接请求并验证。本平台上任何内容均不构成法律、医疗或专业建议。用户在购买任何研究化学品之前应自行核实供应商资质,并确保遵守所有适用的当地、州及联邦法律法规,承担全部法律责任。
阅读完整免责声明